DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05249881

UnknownPhase EARLY_1

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

"Efficacy of Once-weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

2

Recruiting sites

1

Enrollment

300

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥30•HbA1c 7.5-10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05249881
Org study ID07125

Timeline

Milestones

Study first posted2022-02-22actual
Study start2022-03-10actual
Last update posted2022-08-05actual
Primary completion2022-12estimated (month precision)
Study completion2022-12estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Both male and female Type 2 Diabetic patients with age ≥18 years.
•Patients with HbA1c ≥ 7.5 % - ≤ 10.0%
•Patients with BMI ≥ 30

Exclusion criteria

•Patients with Type 1 Diabetes Mellitus
•Patients with Gestational Diabetes Mellitus.
•Patients with Chronic Renal Failure with eGFR of ≤ 30ml/min
•Patient already on another GLP 1 analogue
•The patient stopped any GLP1 analogue treatment less than 3 months back.
•Patients with history of chronic pancreatitis or pancreatic cancer.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Weight Changes in Obese People

Time frame:3 months

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Change in glycemic Index in Diabetes mellitus type-2 Patients

Time frame:3 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.